Seeking Alpha
 

Vericel Corporation (VCEL)

- NASDAQ
  • Tue, Mar. 24, 9:18 AM
    | 3 Comments
  • Tue, Mar. 24, 6:20 AM
    • Vericel (VCEL -2.1%) Q4 results: Revenues: $14.7M (+999%); COGS: $6.8M (+999%); R&D Expense: $5.8M (+75.8%); SG&A: $4.5M (+181.3%); Operating Loss: ($2.3M) (+53.1%); Net Loss: ($2.4M) (+17.2%); Loss Per Share: ($0.17) (+82.5%).
    • FY2014 results: Revenues: $28.8M (+999%); COGS: $17.3M (+999%); R&D Expense: $21.3M (+41.1%); SG&A: $13.8M (+133.9%); Operating Loss: ($23.5M) (-11.9%); Net Loss: ($19.9M) (-27.6%); Loss Per Share: ($2.23) (+67.9%); Quick Assets: $30.3M (+274.1%).
    • No guidance given.
    | Comment!
  • Mon, Mar. 23, 4:04 PM
    • Vericel (NASDAQ:VCEL): Q4 EPS of -$0.17 may not be comparable to consensus of -$0.47.
    • Revenue of $14.7M beats by $4M.
    • Press Release
    | Comment!
  • Nov. 13, 2014, 9:47 AM
    • Aastrom Biosciences (ASTM +3.4%) Q3 results: Revenues: $9.7M; COGS: $5.5M; R&D Expense: $7.8M (+200.0%); SG&A: $4.3M (+290.9%); Operating Loss: ($8M) (-122.2%); Net Loss: ($6.9M) (-200.0%); Loss Per Share: ($0.82) (+31.7%); Quick Assets: $37.6M (+364.2%).
    • No guidance given.
    | Comment!
  • Nov. 13, 2014, 8:21 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q3 EPS of -$0.52 beats by $0.14.
    • Revenue of $9.66M beats by $2.93M.
    • Press Release
    | Comment!
  • Nov. 5, 2014, 5:13 PM
    • Aastrom Biosciences (NASDAQ:ASTM) will report Q3 results on November 13 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.66) per share on revenues of $6.7M.
    | Comment!
  • Oct. 10, 2014, 8:21 AM
    • Aastrom Biosciences (NASDAQ:ASTM) plans to change its name to Vericel Corporation and move its corporate base from Michigan to Cambridge, MA. The name change is contingent on shareholder approval.
    • President & CEO Nick Colangelo says, "The proposed name change and plan to move our headquarters to Cambridge are the next steps in the transformation of Aastrom from a clinical-stage company to a fully integrated commercial-stage specialty biologics company. The new corporate name reflects our leading position in the cell therapy market. Our expanded presence in the vibrant Cambridge biotechnology community will increase our access to both talent and technology as we continue to grow our company, maximize the potential of our two U.S.-marketed products, Carticel and Epicel, and bring our late-stage product candidates, MACI and ixmyelocel-T, to market."
    | Comment!
  • Sep. 11, 2014, 9:22 AM
    • Aastrom Biosciences (NASDAQ:ASTM) prices its public offering of 13,725,490 common shares at $2.55 per share. Underwriters over-allotment is 2,058,823 shares. Closing date is September 16, 2014.
    • Net proceeds will support the company's commercialization activities and fund the Phase 2b ixCELL-DCM clinical trial of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy in addition to general corporate purposes.
    | 4 Comments
  • Sep. 11, 2014, 9:14 AM
    | Comment!
  • Sep. 2, 2014, 12:45 PM
    | Comment!
  • Aug. 22, 2014, 11:07 AM
    • The peer-reviewed journal Circulation Research publishes Aastrom Biosciences' (ASTM +9.1%) Phase 2a clinical trial results for its heart failure therapy candidate ixmyelocel-T as a treatment for advanced heart failure due to ischemic dilated cardiomyopathy (DCM). The study entitled "Safety and Efficacy of Ixmyelocel-T: An Expanded, Autologous Multi-Cellular Therapy, in Dilated Cardiomyopathy" showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM.
    • In two open-label studies, a total of 61 patients were randomized. Fifty-nine were treated with ixmyelocel-T or standard-of-care (SOC). The ixmyelocel-T group experienced fewer MACE events than the SOC group, although the results do not appear to be statistically significant.
    • A poster on an ixmyelocel-T study involving 39 patients disclosed that certain characteristics in the study design made it difficult (translation: impossible) to draw conclusions about efficacy. The only conclusion was the noting of some consistent trends. The published study only involves 20 additional subjects so the "conclusions" are most assuredly the same.
    | 2 Comments
  • Aug. 22, 2014, 9:15 AM
    | Comment!
  • Aug. 14, 2014, 8:30 AM
    • Aastrom Biosciences (NASDAQ:ASTM) Q2 results: Revenues: $4.4M (+999%); Operating Expenses: $7.9M (+51.7%); Net Loss: ($4.6M) (+5.1%); Loss Per Share: ($0.94) (+65.4%); Quick Assets: $7.3M (-9.9%).
    • No financial guidance given.
    | Comment!
  • Aug. 14, 2014, 7:34 AM
    • Aastrom Biosciences (NASDAQ:ASTM): Q2 EPS of -$0.94 may not be comparable to consensus of -$1.02.
    • Press Release
    | Comment!
  • Jun. 4, 2014, 9:26 AM
    • Aastrom Biosciences (ASTM) hires Gerard Michel as its new CFO and VP, Corporate Development. Mr. Micheal joins the firm from Biodel where he had similar duties.
    | Comment!
  • Jun. 2, 2014, 12:50 PM
    | 2 Comments
Visit Seeking Alpha's
VCEL vs. ETF Alternatives
Company Description
Vericel Corpis engaged in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products including Carticel and Epicel.
Sector: Healthcare
Industry: Biotechnology
Country: United States